- Home
- PIRS vs BMRA Comparison
PIRS vs BMRA Comparison
Compare PIRS & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIRS
- BMRA
- Stock Information
- Founded
- PIRS 2001
- BMRA 1971
- Country
- PIRS United States
- BMRA United States
- Employees
- PIRS N/A
- BMRA N/A
- Industry
- PIRS Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PIRS Health Care
- BMRA Health Care
- Exchange
- PIRS Nasdaq
- BMRA Nasdaq
- Market Cap
- PIRS 21.3M
- BMRA 7.4M
- IPO Year
- PIRS N/A
- BMRA N/A
- Fundamental
- Price
- PIRS $16.96
- BMRA $0.34
- Analyst Decision
- PIRS
- BMRA
- Analyst Count
- PIRS 0
- BMRA 0
- Target Price
- PIRS N/A
- BMRA N/A
- AVG Volume (30 Days)
- PIRS 6.3K
- BMRA 68.9K
- Earning Date
- PIRS 11-12-2024
- BMRA 10-15-2024
- Dividend Yield
- PIRS N/A
- BMRA N/A
- EPS Growth
- PIRS N/A
- BMRA N/A
- EPS
- PIRS N/A
- BMRA N/A
- Revenue
- PIRS $20,872,000.00
- BMRA $5,509,000.00
- Revenue This Year
- PIRS N/A
- BMRA N/A
- Revenue Next Year
- PIRS N/A
- BMRA N/A
- P/E Ratio
- PIRS N/A
- BMRA N/A
- Revenue Growth
- PIRS N/A
- BMRA 1.74
- 52 Week Low
- PIRS $6.20
- BMRA $0.24
- 52 Week High
- PIRS $23.20
- BMRA $2.13
- Technical
- Relative Strength Index (RSI)
- PIRS 56.96
- BMRA 50.80
- Support Level
- PIRS $16.09
- BMRA $0.28
- Resistance Level
- PIRS $16.55
- BMRA $0.36
- Average True Range (ATR)
- PIRS 0.29
- BMRA 0.04
- MACD
- PIRS 0.03
- BMRA 0.00
- Stochastic Oscillator
- PIRS 100.00
- BMRA 65.00
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.